|
|
You are searching for "CFAMM00289506" in compound. Total 1 results found.
Click on CFAM IDs and names to search or view in CFAM, click on external IDs to view the entity in its source database.
CFAM Mol ID | CFAMM00289506 |
Family | CFFID3362 Muscarinic acetylcholine receptor M1 and Muscarinic acetylcholine receptor M2 Ligand 1'-benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione Family |
Superfamily | CFSID2332 Muscarinic acetylcholine receptor M1 and Muscarinic acetylcholine receptor M2 Binder Superfamily 3 |
Class | CFCCD249 Class 1062 |
External ID | CHEMBL400517 |
External Source | CHEMBL |
PubChem CID |
44447432 |
Functional Category |
Bioactive |
Molecule Name |
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(cyclopropylmethyl)-4-[(1R,3'R)-3'-methylspiro[indene-1,4'-piperidine]-1'-yl]butanamide |
IUPAC Name |
N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(cyclopropylmethyl)-4-[(1R,3'R)-3'-methylspiro[indene-1,4'-piperidine]-1'-yl]butanamide |
Synonyms |
CHEBI:524006 |
InChi |
InChI=1S/C31H34F6N2O/c1-20-19-39(13-11-29(20)10-8-23-4-2-3-5-27(23)29)12-9-24(14-21-6-7-21)28(40)38-18-22-15-25(30(32,33)34)17-26(16-22)31(35,36)37/h2-5,8,10,15-17,20-21,24H,6-7,9,11-14,18-19H2,1H3,(H,38,40)/t20-,24?,29-/m0/s1 |
InChiKey |
STSDXEDJWCUXPS-RCKAKEGUSA-N |
Formula | C31H34F6N2O |
Molecular Weight | 564.60 |
Cross Link | CHEMBL400517 |
Structure |
|
Statistics of CFAM Database |
CFAM currently contains 490,279 molecules in 87,136 families, 34,880 superfamilies and 11,643 classes. |
How to cite our database |
C. Zhang, L. Tao, C. Qin, P. Zhang, S.Y. Chen, X. Zeng, F. Xu, Z. Chen, S.Y. Yang and Y.Z. CFam: A Chemical Families Database Based on Iterative Selection of Functional Seeds and Seed-Directed Compound Clustering.
Nucl. Acids Res. 43 (D1): D558-D565 (2015) (First published online: November 20, 2014).
|
Last update by |
2014.08.29
|
48680 visits since 2014 .........
Dr.
Chen Yuzong
Deputy
Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|